Brief: Waverley Pharma Provides Update On Its Parp-1 Inhibitor Program
11/01/2023 12:57
Jan 11 (Reuters) - Waverley Pharma Inc WAVE.V :
* WAVERLEY PHARMA PROVIDES UPDATE ON ITS PARP-1 INHIBITOR
PROGRAM
* WAVERLEY PHARMA INC - CURRENT LEAD COMPOUND HAS SINGLE
DIGIT
NANOMOLAR ACTIVITY AND SIGNIFICANT SELECTIVITY TO PARP-1 OVER
PARP-2
* WAVERLEY PHARMA INC- HAS RENEWED ITS FOCUS ON COMPLETING
ITS
PARP-1 PRE-CLINICAL DEVELOPMENT PROGRAM, WHICH IS AT LEAD
OPTIMIZATION STAGE
Source text for Eikon: ID:nCNW8n4Qja
Further company coverage: WAVE.V
((reuters.briefs@thomsonreuters.com;))
Recent news on Waverley Pharma
See all newsBrief: Waverley Pharma Announces Chief Financial Officer Change
Brief: Waverley Pharma Acquires Us Based Pharmacy
Brief: Waverley Pharma Business Update
Brief: Waverley Pharma Provides Update On Its Parp-1 Inhibitor Program
Brief: Waverley Pharma - Co's Unit Awarded Exclusive Distribution Rights For Two Strengths Of Pemetrexed By NHS England